Unlocking the medicinal arsenal of Cissus assamica : GC‐MS/MS, FTIR, and molecular docking insights
Health Science Reports · 2024-09 · 7 (9)
DOI: 10.1002/hsr2.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 25.09.2024. Verfasst von Mohammad Abdullah Taher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bangladesh Reference Institute for Chemical Measurements (BRiCM), Laboratory Road Dhaka Bangladesh. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and aims This study investigated the biochemical components present in the leaves of Cissus assamica . The primary aim was to analyze these components using advanced techniques and assess their potential therapeutic applications. Methodology Fourier Transform Infrared (FT‐IR) spectroscopy, Gas Chromatography‐Mass Spectrometry (GC‐MS), and Mass Spectral analysis were employed to identify and characterize the compounds in Cissus assamica leaves. The mass spectra of each compound were compared with data from the Wiley and NIST libraries to determine their names, molecular masses, and chemical structures. FT‐IR analysis identified characteristic functional groups by their specific frequencies. Results and discussion FT‐IR spectroscopic analysis revealed significant molecular vibrations at frequencies of 3265.63, 2853.81, 1638.60, 1469.21, and 1384.95 cm⁻¹, indicating the presence of specific functional groups. The GC‐MS analysis identified distinct compounds, such as “aR‐Turmerone,” “Curlone,” “7,8‐Epoxylanostan‐11‐ol, 3‐acetoxy‐,” “13‐Docosenamide, (Z)‐,” “Phenol, 3,5‐bis(1,1‐dimethylethyl)‐,” “9,19‐Cyclolanostan‐3‐ol, 24,24‐epoxymethano‐, acetate,” and “Quinoline‐5,8‐dione‐6‐ol, 7‐[[(4‐cyclohexylbutyl)amino]methyl]‐.” These compounds exhibited potential therapeutic applications. Their cytotoxic, antimicrobial, antidiarrheal, anti‐hyperglycemic, and pain‐relieving properties were evaluated by comparing them with reference ligands targeting specific receptors, including dihydrofolate reductase (DHFR), epidermal growth factor receptor (EGFR), kappa opioid receptor (KOR), glucose transporter 3 (GLUT 3), and cyclooxygenase 2 (COX‐2). Conclusion The results of this study suggest that Cissus assamica leaves contain bioactive compounds with potential therapeutic benefits for treating infections, diarrhea, hyperglycemia, and pain. However, further research is needed to conduct comprehensive phytochemical screening and establish the precise mechanisms of action for the crude extract or the plant‐derived compounds.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bangladesh Reference Institute for Chemical Measurements (BRiCM), Laboratory Road Dhaka Bangladesh.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy University of Dhaka Bangladesh.
- Department of Pharmacy State University of Bangladesh Dhaka Bangladesh.
- Department of Chemistry University of Dhaka Bangladesh.
ORCID-Profile: Mohammad Abdullah Taher
Zitieren
APA
Taher, M. A., Kundu, R., Laboni, A. A., Shompa, S. A., Moniruzzaman, M., Hasan, M. M., Hasnat, H., Hasan, M. M., & Khan, M. (2024). Unlocking the medicinal arsenal of Cissus assamica : GC‐MS/MS, FTIR, and molecular docking insights. Health Science Reports, 7(9). https://doi.org/10.1002/hsr2.70091
Vancouver
Taher MA, Kundu R, Laboni AA, Shompa SA, Moniruzzaman M, Hasan MM, et al. Unlocking the medicinal arsenal of Cissus assamica : GC‐MS/MS, FTIR, and molecular docking insights. Health Science Reports. 2024;7(9). doi:10.1002/hsr2.70091
BibTeX
@article{Taher2024,
author = {Taher, Mohammad Abdullah and Kundu, Ripa and Laboni, Aysha Akter and Shompa, Suriya Akter and Moniruzzaman, Md and Hasan, Mohammad Mahmudul and Hasnat, Hasin and Hasan, Md Mehedi and Khan, Mala},
title = {Unlocking the medicinal arsenal of Cissus assamica : GC‐MS/MS, FTIR, and molecular docking insights},
journal = {Health Science Reports},
year = {2024},
volume = {7},
number = {9},
doi = {10.1002/hsr2.70091}
}
EUVIMED